Close Menu

NEW YORK — German molecular diagnostics firm Curetis said today that it has hired US investment bank H.C. Wainwright to help it review strategic options for securing the money it needs to continue operations for at least the next 12 months.

Options under consideration include equity funding, an acquisition, merger, or business combination, Curetis said, adding that it does not intend to provide updates on the strategic assessment until a course of action is selected.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.